Viking is priced for a molecule the aisle cannot see

The 2026 evidence is two. Novo Nordisk and Eli Lilly sit on the molecule side: prescriptions times the price they actually collect. Smucker, PepsiCo, and Hershey sit on the calorie side: units, mix, and whether price can hide a hole. Flatten them and you get a false headline. Do not flatten them.

VK2735 is the named drug

Viking Therapeutics trades as VKTX. The object on this page is VK2735, an investigational GLP-1/GIP dual agonist the company is running through Phase 3 under the VANQUISH program. VANQUISH-1 and VANQUISH-2 are the weight-loss endpoint trials readers will see on the calendar. Phase 1 maintenance data is due in the third quarter of 2026. That date is a composition read, not a revenue line. Clinical-stage companies burn R&D before they book sales. If the trials miss, the next object is often dilution, not a buyback.

VANQUISH is the trial

The food-demand page already named the exposed aisle. Numerator finds a current GLP-1 user in about 22% of households, grocery spend down about 4% in those homes, and roughly two-thirds discontinuing within six months. Foundayo, orforglipron from Eli Lilly, shipped on 1 April 2026 with a once-daily small molecule and a Medicare Part D copay as low as $50 from 1 July. That tablet is an access trade on the incumbent side. VANQUISH is a Phase 3 trade on the challenger side. They share a receptor class. They do not share a 10-Q.

VANQUISH-1 and VANQUISH-2 are the names that belong in the calendar before anyone merges them with Smucker's US Retail volume/mix. A weight-loss endpoint read is a binary object for a clinical-stage equity. It is not a scanner volume line. The maintenance cohort due in the third quarter of 2026 is the other half of the same sentence: whether weight stays off after the acute cut. Persistence is the commercial question. VANQUISH is where Viking tries to answer it in a protocol strangers can cite.

Three prices on one ticker

The share last cleared at $33.86. Over one year the print is up 22.77%. Over three years it is up 145.18%. Year to date it is down 4.40%. Those returns are the tape's memory of a molecule race, not a calorie count. Simply Wall Street's crowd model puts fair value at $92.72 and frames the name as 63.5% undervalued. We report that number because it is part of the public argument around VKTX. We do not adopt it as our price. Our house discounted cash flow prints $7.94. Three prices, one ticker, zero revenue.

That fork is the point. $33.86 is what cleared. $92.72 is what a narrative model thinks the molecule could be worth if VANQUISH sings and the market pays up early. $7.94 is what a sober DCF does with no sales, heavy R&D, and the usual clinical-stage dilution path if the read is ordinary or late. None of those three numbers tells you what happened to Hostess. All three tell you how loud the equity argument is before the trial names a percentage we are not inventing here.

What the aisle cannot do

The calorie-cut companion already did the shelf work. Hostess is the exposed bag. Staples leading a down week for the index is rotation, not proof the aisle is full. A refutation on the food side would look like snack volumes up for two quarters while prescriptions still grow fast. A refutation on the molecule side would look like a VANQUISH miss and a financing. Those two refutations can happen in the same year. They are not the same event.

Do not medicalise a food print into a biotech price. Do not medicalise a biotech price into a food short. Lilly and Novo are on the board because they are the incumbents on the molecule side of GLP-1. Smucker is on the board because it bought the exposed aisle. VKTX is on the board because VANQUISH is the trial this page is about. None of those tickers is a recommendation to own the other trade.

If VANQUISH-1 or VANQUISH-2 reports a primary weight-loss endpoint that meets the protocol in a Viking Therapeutics release, the molecule trade moves and the crowd's $92.72 fork gets a number to argue with. If the read slips or misses and the company files a financing, the house DCF's $7.94 fork gets company. If Phase 1 maintenance in the third quarter of 2026 shows durable weight off drug, persistence becomes part of the equity story. If Hostess prints another volume/mix cut while VANQUISH is still blinded, the aisle moved and the trial did not. Both can be true.

The honest uncertainty is which object gets a number first. Gallup's 11% is a survey. Circana's $231 billion is a category total. $33.86 is a share price. VANQUISH is a trial. Until a primary read lands, the equity argument is the only object that cleared. The snack aisle is the other page.